Pfizer has settled an ongoing battle with Teva Pharmaceuticals and several other parties to prevent the sale of Teva’s copycat version of the world’s best-selling drug, Lipitor (atorvastatin).

Under the terms of the agreement Teva, Phoenix Healthcare Distribution, Barclay Pharmaceuticals, AAH Pharmaceuticals, L Rowland & Co and Day Lewis will not the generic before May 2012, when the patent expires.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Pfizer commenced legal proceedings against Teva and three major wholesalers in July.

Upon the decision of a full trial, Pfizer said in a statement that Teva acknowledges that the Lipitor patent is valid and infringed by Teva’s product.

In November, Pfizer will launch a chewable low-dose version of Lipitor in the EU.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now